HO
Therapeutic Areas
Tiantan Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Human Albumin | Hypovolemia, Burns, Hypoalbuminemia | Approved |
| Human Immunoglobulin (IVIG) | Primary Immunodeficiency, Autoimmune Diseases | Approved |
| Hepatitis B Immunoglobulin (HBIG) | Prevention of Hepatitis B | Approved |
| Tetanus Immunoglobulin | Prophylaxis/Treatment of Tetanus | Approved |
| Rabies Immunoglobulin | Post-exposure Prophylaxis for Rabies | Approved |
| Factor VIII | Hemophilia A | Approved |
| Prothrombin Complex Concentrate (PCC) | Bleeding in Hemophilia B | Approved |
| Inactivated Hepatitis A Vaccine | Prevention of Hepatitis A | Approved |
Leadership Team at Tiantan Bio
RO
Representative of CNBG/Sinopharm
Chairman of the Board
SI
Senior Industry Executive
General Manager / Chief Executive Officer (CEO)
FE
Financial Executive
Chief Financial Officer (CFO)
HO
Head of Vaccine Division
Vice President, Vaccines
HO
Head of Research
Vice President, R&D
HO
Head of Manufacturing
Vice President, Production
HO
Head of Quality
Vice President, Quality Control
HO
Head of Commercial
Vice President, Sales and Marketing
ID
Independent Director
Independent Non-Executive Director